Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 8:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lorcaserin Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lorcaserin in the Treatment of Cocaine Use Disorder

NCT03007394
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Lorcaserin, Placebo Oral Capsule
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 1 Interventional

Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder

NCT02932215
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
lorcaserin, Fitbit Charge HR
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

NCT00828724
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 1, 2026, 8:58 PM EDT
Not listed Phase 2 Interventional

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT03812523
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy
Interventions
Duloxetine 60 mg qd, Lorcaserin
Drug
Lead sponsor
Southeastern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 1, 2026, 8:58 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

NCT03338296
View directory record Official record
Conditions
Obesity
Interventions
lorcaserin hydrochloride XR, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • Bell Gardens, California • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 1, 2026, 8:58 PM EDT
Terminated Phase 1 Interventional

Gene-by-Stress Interactions in Intervention Studies Significance

NCT03011645
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Ziprasidone, Lorcaserin, Placebo Oral Tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 1, 2026, 8:58 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Addressing Post Cessation Weight Gain

NCT02412631
View directory record Official record
Conditions
Obesity, Smoking Cessation
Interventions
lorcaserin, Varenicline, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 1, 2026, 8:58 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

NCT04396847
View directory record Official record
Conditions
Alcohol Use Disorder, Tobacco Smoking
Interventions
Lorcaserin Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
21 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 1, 2026, 8:58 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

NCT04572243
View directory record Official record
Conditions
Epilepsies, Myoclonic
Interventions
Placebo, Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

NCT02019264
View directory record Official record
Conditions
Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions
Lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years and older
Enrollment
14,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
373
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

NCT02022956
View directory record Official record
Conditions
Pharmacokinetics in Obese Adolescents
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

NCT03627936
View directory record Official record
Conditions
Healthy Participants
Interventions
Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

NCT02044874
View directory record Official record
Conditions
Smoking Cessation
Interventions
APD356-lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
31
States / cities
Encino, California • Escondido, California • Los Alamitos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

NCT03253926
View directory record Official record
Conditions
Cannabis Use
Interventions
Lorcaserin, Placebo, Marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

NCT02537873
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Lorcaserin, Cocaine Intravenous (IV), Placebo comparator
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 1, 2026, 8:58 PM EDT
Withdrawn Phase 1 Interventional

Rebalancing the Serotonergic System in Cocaine Dependence

NCT03266939
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Lorcaserin, Placebo Oral Tablet
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

NCT00603902
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
4,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

NCT03143855
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence, Opioid-Related Disorders, Opioid Use
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

NCT00828438
View directory record Official record
Conditions
Renal Impairment
Interventions
Lorcaserin 10mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 1, 2026, 8:58 PM EDT
Terminated Early Phase 1 Interventional Results available

Lorcaserin for Cannabis Use Disorder

NCT03637842
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Lorcaserin, Placebo oral capsule
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 1, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APD356 in the Treatment of Obesity

NCT00104507
View directory record Official record
Conditions
Obesity
Interventions
APD356
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 1, 2026, 8:58 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Predictors of Lorcaserin-Induced Weight Loss

NCT03353220
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Belviq, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 1, 2026, 8:58 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mechanisms of Lorcaserin for Smoking Cessation

NCT04396834
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking Cessation
Interventions
Lorcaserin Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Sep 1, 2026, 8:58 PM EDT
Not listed Phase 4 Interventional

Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study

NCT01962402
View directory record Official record
Conditions
Weight Gain
Interventions
lorcaserin, Intensive dietary counseling
Drug · Behavioral
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Sep 1, 2026, 8:58 PM EDT